57 results about "Corticosteroid" patented technology

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The invention relates to the technical field of nursing, and discloses a bio-based material-containing mesoporous silica oil-control fluffy composition, which comprises the following components: polyglycerol fatty acid esters, a cationic polymer, mesoporous silica, a fat-soluble freshener, a bacteriostatic agent, an anti-inflammatory agent, a scalp oil secretion inhibition composition and the balance of pure water. The care composition disclosed by the invention can realize oil-controlling and fluffy effects from multiple aspects, each raw material plays a beneficial role in oil-controlling and fluffy effects, and the matching of the polyglycerol fatty acid esters, the water-insoluble and soluble organic acids and salts thereof can improve the oil-controlling and fluffy effects of the oil-controlling and fluffy effects of the oil-controlling and fluffy effects. The composition can selectively remove unwanted peroxidized cortex and reduce the removal degree of lipid and moisture of skin, can control grease secretion, improve scalp water-oil balance and avoid entering a'grease control 'vicious circle, and can protect scalp health while controlling grease secretion and keeping scalp fresh and cool.

Compositions and methods are provided for the prevention of osteonecrosis or osteoporosis associated with corticosteroid administration in an individual. The methods of the disclosure comprise administration of an effective dose of a metformin agent, or a derivative, mimetic or analog thereof in combination with administration of a corticosteroid. The effective dose of metformin agent decreases oxidative stress and restores osteogenic capacity of mesenchymal stem cells exposed to a glucocorticoid.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof. In some embodiments, an outcome of the methods of the present technology is increased relative to the same method comprising use of a corticosteroid.

Pharmaceutical compositions comprising adeno-associated virus (AAV) and their use in treating diabetic macular edema are provided herein. In some aspects, treatment methods encompass co-administration of one or more corticosteroids and / or supplemental administrations of aflibercept protein.

The present disclosure relates to pharmaceutical compositions, kits, methods and uses thereof comprising a corticosteroid and an adenovirus-based delivery and expression system. In some embodiments, administration of the compositions, kits, methods, and uses thereof to an animal may improve one or more of transduction, expression, efficacy, and / or safety of an adenovirus-based delivery and expression system as compared to administration of the same pharmaceutical composition without corticosteroids.

The present invention relates to methods, kits, and compositions for testing a sample from a subject with asthma to determine: i) if the subject is A / A or A / C at position 1245 in the HSD3B1 gene, and / or if the subject expresses a 367N version of the 3β-HSD1 protein (e.g., and should be administered a non-corticosteroid for their asthma), or ii) if the subject is C / C at position 1245 in the HSD3B1 gene, and / or if the subject expresses only the 367T version of the 3β-HSD1 protein (e.g., and should be administered a corticosteroid for their asthma). In certain embodiments, the corticosteroid is a glucocorticoid.

Biomaterials, implants, methods of making the biomaterial and implants, methods of providing pain relief by administering the biomaterial or implant to a patient, and kits that include such biomaterials, implants, or components thereof. The biomaterials may include microparticles including one or more active pharmaceutical agents, such as anesthetics, antibiotics, and corticosteroids, which help to provide pain relief over an extended period of time. The biomaterials may be applied directly to the intervertebral disc or in the disc space to provide direct therapy for the management of disc pain.

Orodispersible film (ODF) is an innovative drug formulation that allows for adjustable dosing and improved patient compliance. It is administered into the mouth where it dissolves, making it suitable for children. The present invention provides an optimized ODF gel formulation and an optimal ODF containing therapeutic doses of hydrocortisone-type corticosteroids (HTC). This ODF is thin, flexible and transparent, and suitable for production in hospital pharmacy using standard equipment. The ODF of the invention allows accurate hydrocortisone levels to be released systemically in patients in need thereof, and its good physico-chemical stability is herein demonstrated for several months. This opens up new opportunities for use in pediatric patients, notably for children suffering from congenital adrenal hyperplasia.

Methods and compositions relate to managing chimeric antigen receptor T (CAR T) cell therapy-associated diarrhea in human subjects undergoing such therapy for colorectal cancer (CRC) are disclosed. The CAR T cells target a CRC-associated antigen, such as Guanylate Cyclase C (GCC) or Carcinoembryonic Antigen (CEA). The methods comprise administering a prophylactic regimen to the subject post-infusion of CAR T cells. This regimen includes agents such as vedolizumab, infliximab, or prophylactic budesonide. Subjects are monitored for diarrhea development and severity based on predefined clinical criteria, including stool frequency or stool volume. The methods may further involve a tiered therapeutic algorithm for treating occurring diarrhea, potentially utilizing corticosteroids or antithymocyte globulin (ATG). These approaches aim to reduce the incidence, duration, and severity of CAR T induced diarrhea, thereby improving patient safety and treatment tolerability.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

This disclosure provides combination therapies comprising an anti-BCMA antigen binding protein, such as belantamab mafodotin; an immunomodulatory imide drug (IMiD); a proteasome inhibitor; and a corticosteroid. This disclosure also provides combination therapies for treating newly diagnosed multiple myeloma.

Described herein are mucoadhesive pharmaceutical compositions of corticosteroids, as well as methods of making such pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid in a mucoadhesive system, wherein the mucoadhesive system comprises a rheology-modifying agent and a vehicle for the corticosteroid. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis, or inflammatory bowel disease.

The invention discloses a hydrocortisone compound ointment preparation for treating haemorrhoids, and belongs to the technical field of medicines. The technical problem to be solved is to provide a hydrocortisone compound ointment preparation which has a good hemorrhoid treatment effect and is stable. The hydrocortisone compound ointment preparation comprises the following components in percentage by weight: 0.15%-1% of corticoid, 0.025%-0.1% of a vasoconstrictor, 2%-4% of a local anesthetic, 0.1%-1.5% of L-menthol, 0.02%-0.5% of chlorhexidine acetate and 0.05%-1% of allantoin. The hydrocortisone compound ointment preparation disclosed by the invention has the medicinal effects of relieving pain and discomfort of patients suffering from haemorrhoids, promoting healing and repairing of haemorrhoids tissues, preventing infection and relieving inflammatory response, and has obvious effects of stopping bleeding and relieving swelling and pain in haemorrhoids treatment.

The invention provides a method for preparing inhalable targeted gold nanoparticles for accelerating pulmonary delivery and treating pulmonary inflammation. The method comprises the following steps: preparing plasmids; carrying out plasmid transformation; carrying out protein expression induction; carrying out protein purification; and the gold nanoparticles (Au (at) PEG-RBD NP) combined with the spikes RBD are prepared. Nanoparticles (NP) in air accumulate more readily in lungs with lipopolysaccharide-induced acute respiratory distress syndrome (ARDS) than in healthy lungs and enter alveolar epithelial cells that express angiotensin converting enzyme (ACE) 2 and L-SIGN (both are Spike receptors activated in ARDS hamsters). The nanoparticles (NP) treat tissue damage, oxidative stress, and inflammation more effectively than corticosteroids, and do not remain gold or create toxicity in the major organs one year after inhalation. The gold core can be used for inhibiting p38 alpha mitogen activated protein kinase and polo-like kinase 3. Similar therapeutic effects have been observed in hamsters suffering from hydrochloric acid induced ARDS. This self-therapeutic nanoparticle (NP), when combined with biomimetic and non-invasive delivery, provides a safe, efficient, and targeted treatment for lung inflammation.

Conjugates of corticosteroids and GCPII inhibitors and their use in treating inflammatory bowel disease are disclosed.

The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and / or corticosteroids.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The present innovation provides a tool for measuring acute and long-term stress in farmed fish, based on non-invasive sampling of material for analysis, wherein derivatives of stress hormones are quantified. The material analysed comprises a sample (e.g., feces samples, water samples from cages or tanks holding the farmed fish, and samples collected from filtration of water from cages or tanks holding the farmed fish) collected at any stage during the life cycle as well as scales, fins, blood, mucus, and bile obtained upon slaughtering. The analyte are specific corticoid metabolites and conjugates.

The present invention relates to a topical formulation comprising, as active ingredients, one or more Group 6 inefficient corticosteroids, an emulsified ointment BP, honey, one or more natural oils and optionally salicylic acid; a method of making such topical formulations; and a method of treating psoriasis or a symptom thereof in a subject by applying the topical formulation of the invention to a subject in need thereof.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

This document relates to methods and materials involved in identifying and / or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a neural epidermal growth factor (EGF)-like 1 (NELL-1) polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents (e.g., corticosteroids, cyclosporine, or a B-cell reduction or depletion agent such as Rituximab) to treat a mammal (e.g., a human) having membranous nephropathy are provided.

The present disclosure provides compositions comprising a polyamine synthesis inhibitor, a tyrosinase inhibitor and a corticosteroid, for reducing excess pigmentation. Also provided herein are methods of reducing excess pigmentation in a subject, comprising administering a composition comprising a polyamine synthesis inhibitor, a tyrosinase inhibitor and a corticosteroid to the subject, and uses of the claimed composition. In some examples, the polyamine inhibitor is an ornithine decarboxylase (ODC) inhibitor such as eflornithine (DFMO).

The invention relates to a herbal preparation in the form of film-coated tablets for the supportive treatment of allergic rhinitis and sinusitis, and a process for preparing such a preparation. The preparation according to the invention contains herbal extracts obtained from a mixture of medicinal herbs including Bupleurum root (Radix Bupleurum), Platycodon grandiflorus root (Radix Platycodi grandiflori), Xanthium strumarium fruit (Fructus Xanthii strumarii), Magnolia officinalis flower (Flos Magnoliae), and Oroxylum indicum bark (Cortex Oroxyli indici), in which each herb is used in appropriate amounts to create synergistic anti-inflammatory, anti-allergic, decongestant, expectorant, and immune-enhancing effects on the respiratory mucosa. The preparation also includes a film-coating system containing a film-forming polymer, plasticizer, and coloring agent, along with tablet-forming excipients such as preservatives, fillers, stabilizers, and anti-caking agents in appropriate proportions to create a highly stable film-coated tablet.The preparation according to the invention has the advantages of preserving the active ingredients of the medicinal herbs, increasing stability, improving bioavailability, being convenient to use, and contributing to enhancing the effectiveness of supporting the treatment of symptoms of allergic rhinitis and sinusitis. It is also safe for long-term use because the preparation contains herbal extracts of natural origin that have been used for a long time in traditional medicine, and does not contain synthetic vasoconstrictors, corticosteroids, or antibiotics. In addition, the extraction and purification process helps remove impurities and reduce irritating components, thereby limiting the risk of unwanted side effects with prolonged use.

The present invention relates to topical pharmaceutical compositions comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in the treatment of allergic dermatitis, particularly hypersensitivity to insect bites, in animals using the compositions of the invention are also described.

Pharmaceutical compositions comprising adeno-associated virus (AAV) and their use in treating wet age-related macular degeneration are provided herein. In some aspects, treatment methods encompass co-administration of one or more corticosteroids and / or supplemental administrations of aflibercept protein.

A method for preparing inhalable targeted gold nanoparticles for accelerated lung delivery and treating lung inflammation is provided. The method includes preparing plasmids; performing plasmids transformation; performing protein expression induction; performing protein purification; and preparing spike RBD-conjugated gold nanoparticles (Au@PEG-RBD NPs). The airborne NP preferentially accumulates in lungs with lipopolysaccharides-induced ARDS to healthy lungs and enters alveolar epithelial cells that express angiotensin converting enzyme (ACE) 2 and L-SIGN, both Spike receptors activated in ARDS hamsters. The NP treats tissue injury, oxidative stress, and inflammation more effectively than corticosteroids, without gold retention in major organs or toxicity 1-year post-inhalation. The gold core blocks p38α mitogen-activated protein kinase and polo-like kinase 3. Similar efficacy is observed in hamsters with hydrochloric acid-induced ARDS. The self-therapeutic NPs, when combined with bioinspiration and non-invasive delivery, provide a safe, effective, and targeted treatment for lung inflammation.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention belongs to the technical field of immunodetection, and particularly relates to a specific binding antibody of estradiol as well as a preparation method and application of the specific binding antibody. The present application provides a specific binding antibody against estradiol (E2). The binding protein adopts rational design guided by computational simulation, the complementary determining regions (CDRs) of the binding protein are accurately optimized, the binding protein can target an estradiol characteristic structural domain with high affinity, structural analogues such as oestrone, estriol and corticoid can be effectively distinguished, and the binding protein shows excellent specificity. When being applied to the development of an in-vitro diagnostic kit, the aptamer can realize high-sensitivity and high-specificity quantitative detection of estradiol in a clinical serum sample, and a reliable tool is provided for precise diagnosis and treatment of related diseases.

This description relates to a method for stabilizing the pH of an aqueous composition comprising a drug that is prone to oxidation, said method comprising the addition of an additive to prevent the oxidation of the drug that is prone to oxidation; in particular, this description relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent the oxidation of the corticosteroid; this description also relates to a composition comprising a corticosteroid and an additive to prevent the oxidation of the corticosteroid.